Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference47 articles.
1. Immunotherapy for nonsmall cell lung cancer: a new therapeutic algorithm;Berghmans;Eur Respirat J,2020
2. First-line immunotherapy for non-small-cell lung cancer;Reck;J Clin Oncol,2022
3. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial;Felip;Lancet,2021
4. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial;O'Brien;Lancet Oncol,2022
5. FDA approves atezolizumab as adjuvant treatment for non-small cell lung cancer. 2021. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-adjuvant-treatment-non-small-cell-lung-cancer Accessed: January 23, 2023.